Black Diamond reports mid-stage lung cancer data, continues its hunt for a partner

Black Diamond Therapeutics reported preliminary Phase 2 data for its EGFR inhibitor in lung cancer, but said it will need to find a partner to be able to move into a registrational program. Instead, the ...